NCT04518995已完成3 期
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Concert Pharmaceuticals69 个研究点 分布在 2 个国家目标入组 706 人开始时间: 2020年11月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 706
- 试验地点
- 69
- 主要终点
- Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
研究概览
简要总结
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
- •At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
- •Willing to comply with the study visits and requirements of the study protocol.
排除标准
- •Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
- •Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
- •Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
- •Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
- •Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
研究组 & 干预措施
Placebo
Experimental
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
干预措施: CTP-543 matching placebo (Drug)
CTP-543 8 mg BID
Experimental
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
干预措施: CTP-543 (Drug)
CTP-543 12 mg BID
Placebo Comparator
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
干预措施: CTP-543 (Drug)
结局指标
主要结局
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
时间窗: Week 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
次要结局
- Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20(Weeks 4, 8, 12, 16, and 20)
- Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24(Baseline, Weeks 4, 8, 12, 16, 20, and 24)
- Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24(Weeks 12, 16, 20, and 24)
- Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24(Baseline, Weeks 12, 16, 20, and 24)
- Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24(Weeks 12, 16, 20, and 24)
- Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24(Weeks 12, 16, 20, and 24)
- Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24(Baseline, Weeks 12, and 24)
- Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24(Baseline, Weeks 12, 16, 20, and 24)
- Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24(Baseline, Weeks 12, and 24)
- Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24(Weeks 12, 16, 20, and 24)
- Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24(Week 24)
- Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24(Baseline, Weeks 12, and 24)
- Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24(Baseline, Weeks 12, 16, 20, and 24)
- Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24(Baseline, Weeks 12, 16, 20, and 24)
- Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24(Baseline and Week 24)
研究者
研究点 (69)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)Alopecia AreataNCT04797650Concert Pharmaceuticals517
已完成
2 期
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic PainPainDiabetic NeuropathiesNCT00375960Vernalis (R&D) Ltd50
已完成
2 期
A Study of Crofelemer to Treat Diarrhea Irritable Bowel SyndromeColonic DiseasesDiarrheaGastrointestinal DiseaseIrritable Bowel SyndromeNCT00101725Bausch Health Americas, Inc.245
已完成
3 期
Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing SpondylitisAnkylosing SpondylitisNCT00418548Wyeth is now a wholly owned subsidiary of Pfizer350
已完成
2 期
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy PatientsType 2 Diabetes MellitusChronic Kidney DiseaseNCT01487109Concert Pharmaceuticals170
相关资讯
Sun Pharma Launches Deuruxolitinib for Severe Alopecia Areata in US Market- Sun Pharmaceuticals has launched deuruxolitinib (Leqselvi) in the United States for treating severe alopecia areata in adults, offering 8 mg tablets to patients aged 18 and older.
- Clinical trials demonstrated that approximately one-third of patients achieved 80% or more scalp hair coverage by week 24, with some reaching 90% coverage from an initial average of only 13%.
- Long-term data showed sustained efficacy with 48.8% of patients achieving SALT scores ≤20 by week 68, and 99.6% of initial responders maintaining their response.
- The company has introduced the Leqselvi Support Program offering eligible patients medication for as little as $0 for up to two years with personalized assistance.last yearDeuruxolitinib Shows Promise in Treating Alopecia Areata- Deuruxolitinib, an oral JAK1 and JAK2 inhibitor, has demonstrated significant efficacy in stimulating hair regrowth in adults with moderate to severe alopecia areata.
- The THRIVE-AA1 phase 3 trial showed that deuruxolitinib resulted in significantly higher proportions of patients achieving a SALT score ≤ 20 compared to placebo.
- Patient-reported outcomes indicated higher satisfaction with hair regrowth in patients treated with deuruxolitinib compared to those receiving a placebo.
- The FDA approved deuruxolitinib in July 2024 as a first-line treatment for adults with moderate to severe alopecia areata, marking a significant advancement.last year